Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, JAMA, vol.311, issue.4, pp.378-384, 2000. ,
, ICH E4 Dose response information to support drug registration. ICH Harmonised Tripartite Guideline, EMA, 1994.
Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials, Clinical Cancer Research, vol.23, issue.1, pp.13-20, 2017. ,
Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies, Biometrics, vol.61, issue.3, pp.738-748, 2005. ,
, Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty. Committee for Medicinal Products for Human Use (CHMP), EMA, 2014.
Assessing Dunnett and MCP-Mod based approaches in two-stage dose-finding trials, Biostatistics and Health Sciences, 2019. ,
Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve, Journal of Biopharmaceutical Statistics, vol.17, issue.6, pp.1097-1115, 2007. ,
The Foundations of Statistics, INC, 1954. ,
MCPMod: An R Package for the Design and Analysis of Dose-Finding Studies, Journal of Statistical Software, vol.29, issue.7, pp.1-23, 2009. ,
Adaptive designs for Dose-finding trials, pp.1-206, 2012. ,
Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III, Statistics in Biopharmaceutical Research, vol.2, issue.4, pp.469-486, 2010. ,
Designs to balance cost and success rate for an early phase clinical study, Journal of Biopharmaceutical Statistics, vol.27, issue.1, pp.148-158, 2017. ,
Utility-based optimization of phase II/III programs, Statistics in Medicine, vol.35, issue.2, pp.305-316, 2016. ,
Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot, Statistics in medicine, vol.34, issue.7, pp.1134-1149, 2015. ,
Meta-Analysis of Clinical Dose-Response in a Large Drug Development Portfolio, Statistics in Biopharmaceutical Research, vol.6, pp.302-317, 2014. ,
Etude de la réponse aux médicaments par la modélisation des relations dose-concentration-effet, pp.1-84, 2010. ,
On the use of utility functions for optimizing phase II/phase III seamless trial designs. Therapeutic Innovation & Regulatory Science, Under review, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02491531
A simple introduction to markov chain monte-carlo sampling, Psychonomic Bulletin and Review, vol.25, issue.1, pp.143-154, 2018. ,
Handbook of markov chain monte carlo, pp.3-592, 2011. ,
Utility-based dose-finding in practice: some empirical contributions and recommendations, Annals of Biostatistics & Biometric Applications, 2019. ,
Implementing the batch means method in simulation experiments, Proceedings of the 28th Conference on Winter Simulation, pp.214-221, 1996. ,
An implementation of the batch means method, INFORMS Journal on Computing, vol.9, issue.3, pp.231-318, 1997. ,
Batching methods in simulation output analysis: What we know and what we don't, Proceedings of the 28th Conference on Winter Simulation, pp.122-127, 1996. ,
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials, Annals of Oncology, vol.26, pp.1808-1812, 2015. ,
The Delphi List: A Criteria List for Quality Assessment of Randomized Clinical Trials for Conducting Systematic Reviews Developed by Delphi Consensus, Journal of clinical epidemiology, vol.51, issue.12, pp.1235-1241, 1998. ,
A simulation study to compare new adaptive dose-ranging designs, Statistics in Biopharmaceutical Research, vol.2, pp.487-512, 2010. ,